Edwards Lifesciences’ CFO Ullem sells $1m in shares

Scott Ullem, the Chief Financial Officer of Edwards Lifesciences Corporation, sold approximately $1 million worth of company stock on March 3, 2025, in a transaction executed in Irvine, California, as part of a pre-arranged trading plan. The sale was conducted under a Rule 10b5-1 plan, which allows corporate insiders to establish predetermined schedules for buying or selling shares at a future date, thereby providing a defense against potential accusations of trading on non-public, material information. The transaction involved the sale of 10,000 shares at an average price of $100 per share, according to a Form 4 filing with the U.S. Securities and Exchange Commission. Following this sale, Ullem's direct holdings in the medical device company were reduced, though he retains a significant stake. Such filings are routine disclosures required by federal securities laws whenever corporate officers, directors, or major shareholders engage in transactions involving their company's equity. Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring, has seen its stock performance closely watched by investors. Insider transactions, especially by C-suite executives, are often scrutinized by the market for signals about a company's financial health or executive confidence. However, sales under 10b5-1 plans are typically viewed as less indicative of an insider's personal outlook, as they are scheduled in advance to avoid any appearance of impropriety. The company has not issued any official statement regarding this specific transaction, which appears to be a routine part of personal financial management.